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Objectives: Darunavir is a protease inhibitor that is administered with low-dose ritonavir to enhance its bioavail-
ability. It is prescribed at standard dosage regimens of 600/100 mg twice daily in treatment-experienced patients
and 800/100 mg once daily in naive patients. A population pharmacokinetic approach was used to characterize
the pharmacokinetics of both drugs and their interaction in a cohort of unselected patients and to compare dar-
unavir exposure expected under alternative dosage regimens.
Methods: The study population included 105 HIV-infected individuals who provided darunavir and ritonavir
plasma concentrations. Firstly, a population pharmacokinetic analysis for darunavir and ritonavir was conducted,
with inclusion of patients’ demographic, clinical and genetic characteristics as potential covariates (NONMEMw).
Then, the interaction between darunavir and ritonavir was studied while incorporating levels of both drugs into
different inhibitory models. Finally, model-based simulations were performed to compare trough concentrations
(Cmin) between the recommended dosage regimen and alternative combinations of darunavir and ritonavir.
Results: A one-compartment model with first-order absorption adequately characterized darunavir and ritonavir
pharmacokinetics. The between-subject variability in both compounds was important [coefficient of variation
(CV%) 34% and 47% for darunavir and ritonavir clearance, respectively]. Lopinavir and ritonavir exposure
(AUC) affected darunavir clearance, while body weight and darunavir AUC influenced ritonavir elimination.
None of the tested genetic variants showed any influence on darunavir or ritonavir pharmacokinetics. The simula-
tions predicted darunavir Cmin much higher than the IC50 thresholds for wild-type and protease inhibitor-resistant
HIV-1 strains (55 and 550 ng/mL, respectively) under standard dosing in .98% of experienced and naive
patients. Alternative regimens of darunavir/ritonavir 1200/100 or 1200/200 mg once daily also had predicted
adequate Cmin (.550 ng/mL) in 84% and 93% of patients, respectively. Reduction of darunavir/ritonavir dosage
to 600/50 mg twice daily led to a 23% reduction in average Cmin, still with only 3.8% of patients having concen-
trations below the IC50 for resistant strains.
Conclusions: The important variability in darunavir and ritonavir pharmacokinetics is poorly explained by clinical
covariates and genetic influences. In experienced patients, treatment simplification strategies guided by drug
level measurements and adherence monitoring could be proposed.
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Introduction
Darunavir is a non-peptidic HIV-1 protease inhibitor indicated for
the treatment of HIV infection in antiretroviral treatment-naive
and treatment-experienced adults and paediatric patients aged
≥6 years.1,2 Darunavir is extensively metabolized by cytochrome
P450 (CYP) 3A4 in the liver and intestinal lumen. In vitro studies
indicate that it is a CYP3A4 inhibitor and a substrate and inhibitor
of P-glycoprotein as well.3,4 In order to improve its pharmacoki-
netic profile, darunavir must be co-administered with low doses
of ritonavir, which increase its oral bioavailability and exposure
through CYP3A and P-glycoprotein inhibition.5 However, an
important variability in darunavir levels has been reported that
could lead to sub-optimal drug levels in certain patients. Some
factors, such as demographics, concomitant medication, treat-
ment adherence and protein concentrations, have been shown
to affect protease inhibitor levels. In addition, polymorphisms in
the genes encoding metabolizing enzymes and transporters
could explain some of this variability.6,7 Yet darunavir/ritonavir is
administered at the standard dosage regimen of 800/100 mg
once daily for treatment-naive patients and 600/100 mg twice
daily as a rescue treatment in experienced patients.3,8 In
treatment-experienced patients with no mutations associated
with darunavir resistance at 48 weeks of therapy, the dosage
regimen of 800/100 mg once daily appears non-inferior to the
standard 600/100 mg twice daily. This suggests that this regimen
might be an alternative option in these experienced patients.9,10
A better characterization of darunavir variability in relation to
ritonavir-induced inhibition and other genetic and non-genetic
factors would be useful for clinical practice. The objective of
the present study was to develop a model for darunavir and
ritonavir administered simultaneously in a cohort of HIV-1-
infected patients. The aims were to identify patient characteristics
influencing variability in drug disposition and to characterize
the interaction between the two compounds. The model was
then used to simulate and compare different combinations of
darunavir/ritonavir doses administered once or twice daily.
Methods
Study population
Plasma darunavir and ritonavir levels were obtained from 99 HIV-infected
individuals and measured during routine therapeutic drug monitoring
according to local treatment guidelines. A median of 2 concentration sam-
ples per individual (range 1–12) were collected, drawn between 0.5 and
43.25 h after the last dose intake under steady-state conditions. In add-
ition, darunavir and ritonavir concentrations from six patients participating
in a study on raltegravir disposition were available.11 For these patients,
five samples were drawn at 1, 3, 6, 8 and 12 h post-drug intake. This
study was conducted within the framework of the Swiss HIV Cohort
Study (http://www.shcs.ch). The ethics committees of all participating cen-
tres approved the project and all participants gave written informed con-
sent for genetic testing. A summary of the population characteristics is
presented in Table 1.
Analytical method
Plasma samples were isolated by centrifugation and stored at2208C until
batch analysis. On the day of analysis, samples were inactivated for virus
at 608C for 60 min. Plasma darunavir and ritonavir levels were determined
by HPLC coupled with tandem mass spectrometry (LC-MS/MS) after protein
precipitation with acetonitrile according to our previously reported analyt-
ical method.12 The calibration curves are linear, with lower limits of
quantification of 25 ng/mL for darunavir and 5 ng/mL for ritonavir. The
laboratory participates in an international external quality assurance pro-
gramme for antiretroviral drug analysis [KKGT, Stichting Kwaliteitsbewaking
Klinische Geneesmiddelanalyse en Toxicologie (Association for Quality
Assessment in TDM and clinical Toxicology), The Hague, The Netherlands].
Genotyping
DNA was extracted from peripheral blood mononuclear cells using the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Genotyping was per-
formed with a customized Veracode microarray (Illumina, Eindhoven,
the Netherlands) designed to cover genetic variation in metabolic
enzymes and nuclear receptors.13,14 Thirty-six single-nucleotide poly-
morphisms (SNPs) with proven functional effect in 15 genes possibly
Table 1. Demographic characteristics of the study population
Characteristic Value
Percentage of
study population
Men/women, n/n 81/25 77/23
Age (years), median (range) 49 (19–72)
Body weight (kg), median (range) 70 (37–126)
Height (cm), median (range) 175 (153–191)
White/black, n/n 98/7 93/7
Protease inhibitors (n)
ritonavir 105 100
lopinavir 8 8
atazanavir 7 7
saquinavir 2 2
amprenavir 1 1
Nucleoside/nucleotide reverse transcriptase inhibitors (n)
didanosine 5 5
tenofovir 61 58
lamivudine 32 30
emtricitabine 41 39
Non-nucleoside/nucleotide reverse transcriptase inhibitors (n)
efavirenz 8 8
nevirapine 1 0.9
etravirine 48 46
Integrase inhibitors (n)
raltegravir 43 41
Others (n)
maraviroc 5 5
enfuvirtide 14 13
AST (U/L), median (range) 27 (11–172)
ALT (U/L), median (range) 26 (8–169)
Total bilirubin (mmol/L),
median (range)
8 (5–14)
CD4+ cell count (cell/mm3),
median (range)
332 (19–1496)
HIV RNA level (copies/mL),
median (range)
0 (0–59700)
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relevant to darunavir and ritonavir metabolism in Caucasians were avail-
able for 60 individuals. Four genes encode enzymes involved in drug
metabolism and 13 genes encode nuclear receptors (Table 2). Nuclear
receptors of the orphan nuclear receptor superfamily have been shown
to regulate the genes that encode CYP enzymes involved in metabolism
of endogenous and exogenous compounds. In addition, three polymorph-
isms associated with two transporter genes (ABCB1, rs1128503; ABCB1,
rs1045642; and ABCC2, rs717620) were available for a subset of 25
individuals.6
Model-based pharmacokinetic modelling
The model-building process included three steps: (i) a population pharma-
cokinetic model was built for darunavir; (ii) a population pharmacokinetic
model was built for ritonavir; and (iii) a model describing the interaction
between the two drugs was developed considering either competitive or
non-competitive inhibition, while taking into account variables potentially
influencing the pharmacokinetics of each drug.
Structural models
A stepwise procedure was used to find models that fitted the darunavir
and ritonavir data best, comparing one- and two-compartment models
with first-order absorption from the gastrointestinal tract. The final phar-
macokinetic model was a one-compartment model with first-order
absorption and elimination for both drugs. The estimated parameters
were clearance (CL), volume of distribution (V) and absorption rate con-
stant (ka). Since darunavir and ritonavir were only administered orally, CL
and V represent apparent values (CL/Fand V/F, respectively, where F is oral
bioavailability). Exponential errors following a log-normal distribution were
assumed for the description of between-subject variability of the
Table 2. Summary characteristics and influence of the genetic variants on darunavir log CL in the GAM analysis
Gene group Gene dbSNP_rs Chromosome Chromosome position Allele change DAIC
CYPs CYP3A5 rs776746 7 99108475 TC 1.392
CYPs CYP3A7 rs10211 7 99140930 TC 1.403
CYPs CYP3A7 rs2257401 7 99144621 GC 20.195
CYPs CYP3AP5 rs6945984 7 99186264 TC 1.781
CYPs CYP3A4 rs4646437 7 99203019 GA 0.5
CYPs CYP3A4 rs4987161 7 99204017 AG 0
CYPs CYP3A4 rs2740574 7 99220032 TC 1.615
NRs NR1I2 rs3814055 3 120982725 CT 0
NRs NR1I2 rs2276706 3 120983997 GA 0
NRs NR1I2 rs12721607 3 121008893 GA 1.896
NRs NR1I2 rs12721608 3 121013109 GA 0
NRs NR1I2 rs6785049 3 121016423 AG 1.077
NRs NR1I2 rs1054190 3 121019408 CT 1.792
NRs NR1I2 rs6438550 3 121019507 AG 20.346
NRs NR1I2 rs3814058 3 121019981 TC 1.289
NRs PPARG rs1801282 3 12368125 CG 0.182
NRs PPARG rs1899951 3 12369840 GA 1.205
NRs PPARGC1A rs8192678 4 23424760 CT 1.953
NRs NR3C1 rs41423247 5 142758768 GC 1.997
NRs NR3C1 rs6198 5 142637814 TC 1.714
NRs ESR1 rs2234693 6 152205028 TC 20.089
NRs AHR rs2066853 7 17345635 GA 2
NRs AHR rs2074113 7 17340296 GT 2
NRs NR1H4 rs56163822 12 99411232 GT 1.608
NRs VDR rs2228570 12 46559162 AG 0.394
NRs VDR rs1544410 12 46526102 CA 1.166
NRs VDR rs11568820 12 46588812 CT 1.767
NRs HNF1A rs1169288 12 119901033 AC 0.443
NRs HNF1A rs2244608 12 119901371 AG 1.97
NRs HNF1A rs2650000 12 119873345 CT 1.621
NRs HNF4A rs1800961 20 42475778 CT 0
NRs PPARA rs4253778 22 45009298 GC 20.304
NRs PPARA rs1800206 22 44992938 CG 21.021
NRs NR1I2 rs6785049 3 121016423 AG 20.852
NRs HNF1A rs1169288 12 119901033 AC 20.5813
NRs HNF1A rs2650000 12 119873345 CT 22.505
NRs, nuclear receptors.
DAIC¼AICi – AICtot or AICi – AICmin in relation to the best model.
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pharmacokinetic parameters and a proportional error model was used to
model the residual variability.
Covariate models
Analyses of covariate effects were performed in two main steps: (i) the
influence of demographic characteristics, concomitant medications and
markers of hepatic function was assessed by incorporating them directly
in the model; and (ii) the impact of candidate SNPs with functional effect
was tested using graphical plots and a generalized additive model (GAM)
using the stepwise method in R (R Foundation for Statistical Computing,
Vienna, Austria, http://www.R-project.org/). This GAM analysis was per-
formed for 36 SNPs of metabolizing enzyme and nuclear receptors avail-
able for 60 patients using log-transformed Bayesian individual estimates
of CL. The analysis first included all SNPs, then SNPs were dropped one by
one with replacement, and the difference in the Akaike criterion (DAIC)
was computed for each SNP. Only significant SNPs were tested for signifi-
cance in the models. In addition, the three SNPs in genes encoding trans-
porters available for a subset of 25 patients were directly tested for
significance in the model building.
Covariates (continuous variables centred on the mean and categorical
covariates being coded as indicator variables, as 0 or 1) were incorporated
in the models, testing linear and non-linear relationships. The demo-
graphic covariates available were sex, race, age, body weight and height;
other covariates were aspartate aminotransferase (AST) and alanine ami-
notransferase (ALT) in addition to antiretroviral co-medications. Genetic
variants were classified according to the number of allelic variants into
three groups (reference allele, heterozygote and homozygote rare allele
groups) coded as indicator variables 0, 1 and 2, respectively.
Darunavir/ritonavir interaction models
Different models were tested to describe the interaction between ritonavir
and darunavir. First, non-competitive models based on ritonavir AUC
(AUCRTV) were explored using linear, power and exponential functions, as
follows:
CL = CL0 − u1 · (AUCRTV −mean AUCRTV) (1)
CL = CL0 · AUCRTVmean AUCRTV
( )−u1
(2)
CL = CL0 · 1EXP(u1 · AUCRTV) (3)
where CL0 is the mean population CL, u1 is the factor associated with the
effect of ritonavir on darunavir CL and mean AUCRTV was 4.56 mg.h/L in the
study population. AUCRTV (from 0 to 12 or 24 h) was derived from the final
model incorporating covariates that best described ritonavir plasma levels,
using DoseRTV/CLind.
In the next step, the inhibition of darunavir clearance by ritonavir was
tested assuming competitive inhibition and modelled using a direct
concentration-dependent relationship of the form CL¼CL0.I(t), where
CL0 is the mean darunavir clearance and I(t) describes a linear, exponential
or Emax-type inhibitory time-dependent model induced by ritonavir con-
centrations (CRTV), as follows:
I = 1− (u1×CRTV) (4)
I = 1
EXP(u1×CRTV) (5)
I = 1− Imax×CRTV(IC50+CRTV) (6)
where u1 is the parameter associated with the influence of CRTV, Imax is the
maximum inhibitory effect of ritonavir and IC50 is the CRTV producing 50%
of the Imax. The same approach was applied to test the influence of dar-
unavir on ritonavir clearance, using AUCDRV, derived as DoseDRV/CLind
(mean AUCDRV¼51.8 mg h/L) or instantaneous darunavir concentration
(CDRV) in direct competitive inhibition models.
Parameter estimation and selection
NONMEMw15 (version VII, NM-TRAN, version II) was used with the FOCE
INTERACTION method to fit the data. The minimum objective function
value (OFV) provided by NONMEMw (22 log likelihood, approximate x2 dis-
tribution) was used to discriminate between models using the likelihood
ratio test. A model was considered superior to another nested model
when the OFV value was reduced by ≥3.84 points (P,0.05). Covariate
analysis comprised forward selection of influential factors followed by
backward deletion and influential factors were retained in the final
model at the statistical level of P,0.01. Model assessment was based
on diagnostic plots (goodness-of-fit plots and visual predictive checks)
along with the standard errors, the correlation matrix of parameter esti-
mates and the size of residual errors.
Model validation
The stability and performance of the final population pharmacokinetic
model were validated by the bootstrap method using 2000 resamplings
with replacement. The final population pharmacokinetic model was fitted
repeatedly to the 2000 bootstrapped samples and the pharmacokinetic
parameters were calculated for each dataset. The median and 95% CI
of each parameter obtained with the bootstrapped data were then com-
pared with the corresponding parameters obtained with the original data-
set. The statistical analysis was performed using Perl-speaks-NONMEM
(version 3.2.4: http://psn.sourceforge.net/). The final model was also
validated using a visual predictive check (VPC). Using the parameter values
of the final population pharmacokinetic model, we simulated data
for 1000 individuals and generated 2.5th, 50th and 97.5th percentiles.
The observed concentrations were plotted against the 95% prediction
interval (PI) of the simulated dataset at each timepoint and visually com-
pared. The figures were generated using GraphPad Prism (Version 6.0
for Windows, GraphPad Software, San Diego, CA, USA; http://www.
graphpad.com).
Simulations
Monte Carlo simulations of darunavir and ritonavir were performed for
1000 individuals based on the final models for darunavir (including the
effect of simulated AUCRTV and assuming no lopinavir intake) and ritonavir
(for a 70 kg individual with average AUCDRV). They were used to predict
darunavir Cmin for various combinations of darunavir and ritonavir in once-
daily or twice-daily dosage regimens (800/100 mg once daily and 600/
100 mg twice daily, 1200/100 mg once daily, 1200/200 mg once daily,
800/50 mg once daily and 600/50 mg twice daily). Simulated darunavir
average Cmin and 95% PI at steady state were compared between the
different dosage regimens. The percentage of patients with a Cmin less
than the 50% effective concentration (EC50) for darunavir corrected for
protein binding for both wild-type (55 ng/mL) and protease inhibitor-
resistant HIV-1 strains (550 ng/mL) served for dosage regimen compari-
sons as well.16 – 18
Results
A total of 289 observations of both darunavir and ritonavir con-
centrations were obtained from 105 HIV-positive individuals and
were included in the population pharmacokinetic analysis.
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Population pharmacokinetic analysis of darunavir
Darunavir concentration measurements ranged between 17 and
14635 ng/mL at doses between 300 and 2400 mg, given once
daily or twice daily A one-compartment model with first-order
absorption from the gastrointestinal tract fitted the data ap-
propriately and the addition of a second compartment did not sig-
nificantly improve the fit (DOFV¼22). No lag time in absorption
was observed (DOFV¼0.0). Assignment of interindividual variabil-
ity to V and ka in addition to CL did not improve the model fit
(DOFV¼0.0).
Among the demographic covariates tested, body weight
showed a linear influence on darunavir pharmacokinetics
(DOFV¼24.3, P¼0.03), suggesting a 43% increase in darunavir
clearance on body weight doubling. The inclusion of lopinavir in
CL improved the fit (DOFV¼24.18, P¼0.04); darunavir CL was
increased by 48% in the presence of this drug.
The GAM regression analysis testing for the influence of genetic
variants on darunavir elimination is presented in Table 2. Two SNPs
(rs1801282 and rs2650000 of the PPARG and HNF1A genes,
respectively) provided the minimum AIC (AICmin¼26.78).
However, only rs2650000 (DAIC¼22.505, P¼0.039) showed a
significant influence on darunavir log CL. Both SNPs were tested
in NONMEM but neither showed any significant improvement
of the fit (rs1801282, DOFV¼21.84, P¼0.175; rs2650000,
DOFV¼25.69, P¼0.017). The influence of ABCB1 rs1128503,
ABCB1 rs1045642 and ABCC2 rs717620 tested on darunavir
pharmacokinetics in a subset of 25 patients was insignificant.
Population pharmacokinetic analysis of ritonavir
Ritonavir was administered at the dose of 100 mg once daily,
except in five patients who received 200 mg once daily; resulting
concentrations ranged between 0 and 5195 ng/mL. A one-
compartment model with first-order absorption from the gas-
trointestinal tract fitted the data appropriately, whereas a
two-compartment did not improve the description of the data
(DOFV¼+5.0). In addition to CL, assignment of interindividual
variability to V (DOFV¼230.1, P,0.001) and a covariance term
between CL and V (DOFV¼24.6, P,0.05) improved the model.
The data did not support the addition of an absorption lag time
(DOFV¼21.0) or the assignment of variability to ka (DOFV¼0.0).
Among the demographic covariates tested, body weight influ-
enced ritonavir pharmacokinetics (DOFV¼216.9, P,0.001); we
estimated a 100% increase in CL upon body weight doubling.
Gender, height and age also had an impact on ritonavir exposure
(DOFV¼211.6,217.03 and26.9, respectively) but were all corre-
lated to body weight. No influence of any of the available covari-
ates was observed on V.
The results of the stepwise GAM analysis are presented in
Table 3. For ritonavir, three SNPs (rs6785049, rs1169288 and
rs2650000, of NR1I2, HNF1A and HNF1A, respectively) were
associated with the lowest AIC. Only two SNPs, rs6785049
(DAIC¼25.513, P¼0.0085) and rs2650000 (DAIC¼23.881,
P¼0.019), showed a significant influence on ritonavir log CL.
These SNPs were included in the modelling steps but none showed
any significant improvement of model fit (rs1169288 snp28,
DOFV¼20.24 for 3 df, P¼0.970; rs6785049, DOFV¼24.07 for 3
df, P¼0.254; rs2650000, DOFV¼22.50 for 3 df, P¼0.475.) The
effects of rs1128503, rs1045642 and rs717620 tested in a subset
of patients did not significantly affect ritonavir pharmacokinetics
either (DOFV,2.06, P¼0.15).
Darunavir/ritonavir interaction models
The influence of ritonavir on darunavir CL was best described using
a power function of AUCRTV (equation 2) (DOFVV¼29.4, P¼0.001
compared with the model without integration of AUCRTV),
whereas the linear and exponential model fitted the data slightly
worse (DOFVV.25.7). A 16% reduction in darunavir CL was
expected upon AUCRTV doubling; this model explained 7% of inter-
individual variability in darunavir clearance. The analysis of daru-
navir and ritonavir incorporating both drug plasma concentrations
using competitive models based on either linear (equation 4) or
exponential (equation 5) components did not improve the good-
ness of fit (DOFVV.22.5). The Imax model (equation 6) better
described the data, with an estimated EC50 of 0.19 mg/L and an
Imax of 55% (DOFVV¼24.4, P,0.05). Since the assignment of
AUCRTV provided the best fit and largest drop in OFV, this effect
was kept in the final model.
The combination of statistically relevant covariates with
respect to darunavir CL revealed that only AUCRTV and lopinavir
remained significant (DOFVV¼214.6, P,0.001) and explained
only 9% of the interindividual variability in darunavir levels.
For ritonavir, the inclusion of AUCDRV for CL improved the fit. The
use of a power function (equation 2) best described this inter-
action (DOFVV¼217.0, P,0.0001). Doubling AUCDRV resulted
in a 24% lower ritonavir CL. Similarly to darunavir, the use of
inhibitory competitive models did not describe the data better.
The multivariate analysis showed that both body weight and
AUCDRV remained significant with respect to CL (DOFVV¼211.6,
P,0.001) and explained 16% of its variability. The final population
pharmacokinetic parameters for darunavir and ritonavir are pre-
sented in Tables 4 and 5, respectively, and goodness-of-fit plots
of population and individual predictions for both drugs are given
in Figure S1 (available as Supplementary data at JAC Online).
Model validation
The median parameter estimates obtained by bootstrapping with
the 90% CI are presented in Tables 4 and 5. Median parameters
differed by ,10% from those obtained with the original dataset.
The parameter estimates of the final population pharmacokinetic
model lay within the 95% CI of the bootstrap results, suggesting
that the model was acceptable. The VPC of the observed darunavir
concentrations versus time with the 90% PI for the standardized
dosing regimen of 600/100 mg twice daily and 800/100 mg once
daily are shown in Figure 1.
Simulations
Simulations based on the final model for darunavir/ritonavir 600/
100 mg twice daily yielded a median Cmin of 2863 ng/mL (95% PI
725–9726 ng/mL), whereas the median Cmin was 981 ng/mL (95%
PI 110–4449 ng/mL) for 800/100 mg once daily. Although average
Cmin would be above the targets of 550 and 55 ng/mL for naive
and experienced patients, respectively, 28% of the patients on the
800 mg once-daily regimen would present levels under the 550 ng/
mL threshold due to the large interpatient variability. Increasing the
once-daily regimen to 1200/100 mg or 1200/200 mg would result
Population pharmacokinetics of darunavir
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in an average Cmin of 1472 ng/mL (95% PI 166–6673 ng/mL) and
2150 ng/mL (95% PI 327–8814 ng/mL), respectively. The regimen
of 1200/100 mg darunavir once daily would decrease the number
of patients below the cut-off of 550 ng/mL to 16% while increasing
ritonavir boosting to 200 mg once daily would reduce it to ,7%.
Reduction of the ritonavir dose from 100 to 50 mg in the 600 mg
twice-daily regimen would lead to an average Cmin of 2174 ng/mL
(95% PI 490–7754 ng/mL). Figure 2 represents darunavir Cmin
predicted after simulations of the different dosage regimens.
Discussion
A population pharmacokinetic analysis of both darunavir and
ritonavir incorporating the relationship between ritonavir expos-
ure and darunavir elimination was developed. Darunavir and
ritonavir pharmacokinetic parameters are in line with previously
reported values of population pharmacokinetic studies.7,19 The
current analysis supports the limited influence of demographic
covariates on darunavir pharmacokinetics. The small influence
of age previously reported was not confirmed in the present
study.20 The reported influence of a-1-acid glycoprotein on the
darunavir volume of distribution could not be tested because
this information was not available.7 Despite the small number
of individuals on lopinavir (n¼8), we found that this drug
increased darunavir CL by 48%, as previously reported.5,21 Due
to their mutual interaction, co-administration of the two drugs
is not recommended.
Darunavir is administered with low doses of ritonavir as a
booster to enhance its pharmacokinetic profile. The exact mech-
anism of CYP3A inhibition by ritonavir is not clearly established,
Table 3. Summary characteristics and influence of the genetic variants on ritonavir log CL in the GAM analysis
Gene group Gene Chromosome dbSNP_rs Chromosome position (build 36) Allele change DAIC
CYPs CYP3A5 7 rs776746 99108475 TC 24.39
CYPs CYP3A7 7 rs10211 99140930 TC 20.34
CYPs CYP3A7 7 rs2257401 99144621 GC 2
CYPs CYP3AP5 7 rs6945984 99186264 TC 1.75
CYPs CYP3A4 7 rs4646437 99203019 GA 1.89
CYPs CYP3A4 7 rs4987161 99204017 AG 0
CYPs CYP3A4 7 rs2740574 99220032 TC 1.96
NRs NR1I2 3 rs3814055 120982725 CT 0
NRs NR1I2 3 rs2276706 120983997 GA 0
NRs NR1I2 3 rs12721607 121008893 GA 20.35
NRs NR1I2 3 rs12721608 121013109 GA 0
NRs NR1I2 3 rs6785049 121016423 AG 20.49
NRs NR1I2 3 rs1054190 121019408 CT 0.49
NRs NR1I2 3 rs6438550 121019507 AG 2
NRs NR1I2 3 rs3814058 121019981 TC 1.33
NRs PPARG 3 rs1801282 12368125 CG 0.45
NRs PPARG 3 rs1899951 12369840 GA 0.1
NRs PPARGC1A 4 rs8192678 23424760 CT 1.12
NRs NR3C1 5 rs41423247 142758768 GC 1
NRs NR3C1 5 rs6198 142637814 TC 0.2
NRs ESR1 6 rs2234693 152205028 TC 1.23
NRs AHR 7 rs2066853 17345635 GA 0.11
NRs AHR 7 rs2074113 17340296 GT 0.14
NRs NR1H4 12 rs56163822 99411232 GT 1.98
NRs VDR 12 rs2228570 46559162 AG 1.53
NRs VDR 12 rs1544410 46526102 CA 1.45
NRs VDR 12 rs11568820 46588812 CT 0.55
NRs HNF1A 12 rs1169288 119901033 AC 1.98
NRs HNF1A 12 rs2244608 119901371 AG 1.04
NRs HNF1A 12 rs2650000 119873345 CT 21.96
NRs HNF4A 20 rs1800961 42475778 CT 0
NRs PPARA 22 rs4253778 45009298 GC 2
NRs PPARA 22 rs1800206 44992938 CG 20.54
NRs NR1I2 3 rs6785049 121016423 AG 25.513
NRs HNF1A 12 rs1169288 119901033 AC 21.524
NRs HNF1A 12 rs2650000 119873345 CT 23.881
NRs, nuclear receptors.
DAIC¼AICi – AICtot or AICi – AICmin in relation to the best model.
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with reports of reversible competitive and mechanism-based
inhibition.22,23 We found that the impact of ritonavir on darunavir
pharmacokinetics was governed by the overall ritonavir exposure,
which is in agreement with previous studies reporting that ritona-
vir inactivates CYP3A through a mechanism-based inhibition.23
Competitive inhibitory models have also been proposed,21,24 sug-
gesting that ritonavir may act via both competitive and non-
competitive inhibition. The results of this study indicate that a
doubling of ritonavir dose and thus the AUCRTV would be
associated with an average 16% decrease in darunavir elimin-
ation, a value far below the important variability observed in
ritonavir pharmacokinetics. Yet this effect explained no more
than 3% of the interpatient variability in darunavir CL, which
remains largely unexplained.
The population pharmacokinetics analysis of ritonavir pro-
duced parameters comparable to those reported in previous
studies.6,19,21,24 The effect of body weight on ritonavir elimination
was responsible for 6% of the between-subject variability in
Table 4. Final population pharmacokinetic parameters for darunavir with median and 90% CI of the pharmacokinetic parameters obtained from the 200
bootstrapped samples
Parameters
Final population
pharmacokinetic parameters Bootstrap (n¼2000 samples)
estimate SE (%)a median SE (%)a 90% CI
CL/F (L/h) 10.9 4.8 10.85 5.1 9.6 12.3
V/F (L) 121.2 11.2 121.3 11.9 80.2 156.9
ka (h
21) 1.04 32.7 1.09 35.4 0.4 2.4
uAUC RTV
b 20.25 27.4 20.24 30.2 20.48 20.06
uLPV
c 0.48 46.3 0.49 51.3 0.06 1.64
v (CL/F) (CV%)d 34.0 47.5e 33.09 49.1e 24.8e 39.5e
s (CV%) 44.0 25.8e 43.8 27.1e 35.4e 53.7e
CL/F, mean apparent clearance; V/F, mean apparent volume of distribution.
Final model: CL/Fi = CL/F×((AUCRTV/4.52)uAUCRTV)×(1+uLPV×LPV).
aStandard errors of the estimates (SE), defined as SE/estimate and expressed as percentages.
bRelative influence of the AUC of ritonavir on darunavir clearance (see text).
cRelative influence of the prescription of lopinavir on darunavir clearance (see text).
dEstimate of between-subject variability, expressed as CV (%).
eStandard errors of the coefficient of variation, taken as SE/(estimate×2) and expressed as a percentage.
Table 5. Final population pharmacokinetic parameters for ritonavir with median and 90% CI of the pharmacokinetic parameters obtained from the 200
bootstrapped samples
Parameters
Final population
pharmacokinetic parameters Bootstrap (n¼2000 samples)
estimate SE (%)a median SE (%)a 90% CI
CL/F (L/h) 20.5 6.8 20.2 7.3 17.0 23.7
V/F (L) 50.6 36.9 48.3 37.2 17.1 85.7
ka (h
21) 0.14 13.6 0.14 13.6 0.10 0.19
uBW
b 1.02 23.4 0.99 25.7 0.58 1.51
uAUC DRV
c 20.38 28.1 20.39 30.6 20.69 20.18
v (CL/F) (CV%)d 46.8 46.9e 46.2 46.2e 31.3 57.7
Correlation CL/V 70.9 59.4 71.8 64.4 38.1 105.6
v (V) (CV%)d 156.7 66.2e 164.4 69.3e 92.3 369.9
s (CV%)d 50.8 28.3e 50.6 31.5e 41.1 61.5
CL/F, mean apparent clearance; V/F, mean apparent volume of distribution.
Final model: CL/Fi = CL/F×((AUCDRV)/52)uAUCDRV×(1+uBW×FBW) with FBW = (BW− 70)/70.
aStandard errors of the estimates (SE), defined as SE/estimate and expressed as percentages.
bRelative influence of body weight on ritonavir clearance (see text).
cRelative influence of the AUC of darunavir on ritonavir clearance (see text).
dEstimate of variability (between-subject v and residual s), expressed as CV (%).
eStandard errors of the coefficient of variation, estimated as SE/(estimate×2) and expressed as a percentage.
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Figure 1. (a) Darunavir (DRV) concentrations versus time standardized for 600/100 mg twice-daily (left panel) and 800/100 mg once-daily (right panel)
dosing. (b) Ritonavir (RTV) concentrations versus time standardized after the darunavir/ritonavir 600/100 mg twice-daily (left panel) and 800/100 mg
once-daily (right panel) regimens. The continuous line represents the population prediction from the final model and the broken lines represent the
95% PI.
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Figure 2. Simulated darunavir (DRV) minimal concentrations (Cmin) for various combinations of darunavir and ritonavir doses. Each box represents the
median and IQR and the bar represents the 95% PI. The horizontal broken line represents the average EC50 for protease inhibitor-resistant HIV strains
(550 ng/mL). bid, twice daily; qd, once daily.
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ritonavir disposition and confirmed a previous finding.7 Darunavir
is a potent inhibitor of CYP3A44 and an influence of this drug was
found on ritonavir CL as well. The mutual inhibition of the two
drugs’ elimination might add to the synergistic effect of this
association.
Genetic variants have been shown to affect the pharmacokin-
etics of many protease inhibitors.25 In the current study, the phar-
macogenetic discovery analysis did not reveal any genetic variant
that could possibly explain some of the variability in the pharma-
cokinetics of darunavir or ritonavir. The study was, however, only
powered to detect strong genetic effects and, except for a small
subset of participants, we did not have genetic information on
drug transporters. So far, no genetic influences on darunavir
pharmacokinetics have been reported in the literature, except
for a recent report on the influence on darunavir CL and central
V of two SNPs (rs8027174 and rs4294800) located in the
SLC03A1 locus.7 These findings need validation because, among
the 148 SNPs investigated, only two intronic SNPs with unknown
functional effect on SLCO3A1 expression or transport activity
show a nominally significant effect, which is not retained after
multiple comparisons correction.7 There is no in vitro or in vivo evi-
dence that darunavir can interact with the SLCO3A1 transporter
as either substrate or inhibitor. No influence of genetic variability
associated with genes encoding blood–brain barrier transporters
has been observed either.26
So far, target Cmin values for darunavir associated with viro-
logical response have not been formally determined. In addition,
there is limited value in considering drug exposure data separately
from information on resistance for the prediction of the virological
response to salvage antiretroviral therapy. Nevertheless, the
protein-adjusted EC50 for both wild-type (55 ng/mL) and protease
inhibitor-resistant (550 ng/mL) HIV-1 strains can serve as useful
targets to evaluate the likely efficacy of a given regimen for a
given virus isolate.16,18,27 In this study, the simulation of daruna-
vir/ritonavir 600 mg twice daily and 800 mg once daily provided
an average darunavir Cmin substantially above the putative targets
of 550 and 55 ng/mL for naive and experienced patients, respect-
ively. However, taking into account the variability of darunavir
pharmacokinetics, about one-third of the patients under the
800 mg once-daily regimen would present levels under the
550 ng/mL threshold, thus justifying the idea that this regimen
can be considered sub-optimal in patients with resistant HIV-1
strains. The shorter elimination half-life estimated in this study
(7 h) compared with the 15 h reported by the manufacturer2
could be the consequence of a change in patients’ adherence pat-
terns over time, leading to lower levels of darunavir, and thus a
shorter apparent elimination half-life. It has been reported that
darunavir concentrations are reduced by nearly half compared
with baseline after 48 weeks of therapy.17 Although a large propor-
tion of treatment-experienced patients might still benefit from a
once-daily darunavir/ritonavir dosing schedule, this strategy is less
forgiving against the possibility of missed doses than twice-daily
administration and should only be considered in highly adherent
patients with a limited number of mutations in their HIV strains.
Considering the growing interest in once-daily administration
of darunavir, we tested alternative regimens that would be useful
in treatment-experienced patients in particular. The 1200 mg dar-
unavir once-daily schedule boosted with 100 or 200 mg of ritona-
vir would decrease the probability of having concentrations below
the cut-off of 550 ng/mL. Although losing the benefit of halving
the daily dose of ritonavir, the once-daily dosing regimen would
offer the possibility of improving convenience and potentially
patient compliance while maintaining higher plasma concentra-
tions over the dosing interval in the presence of drug resistance.
Reduction of the booster could be beneficial in some patients,
as previously suggested by the potential improvements in adverse
events or lipid profiles for tipranavir28 and atazanavir.29 Although
the darunavir/ritonavir 600/50 mg twice-daily regimen resulted in
23% lower average Cmin, only a few patients would present con-
centrations below the EC50 of 550 ng/mL. This result is in good
agreement with a 30% decrease in darunavir exposure predicted
after reducing ritonavir from 100 to 50 mg once daily.7
In conclusion, a population analysis was used to predict
the pharmacokinetic parameters of darunavir in the presence of
ritonavir. Darunavir variability was large and only to a small extent
explained by ritonavir exposure, which exhibited important
between-subject variability as well. No influence of other covariates
or genetic polymorphism was found, potentially due to the rela-
tively small population size and the low allelic frequency of some
of the polymorphisms. The concentrations predicted under the
standard 600/100 mg twice-daily regimen for treatment-experi-
enced patients and 800/100 mg once daily for naive or experienced
patients with limited resistance-associated mutations lay within a
safe margin with regard to the EC50 for wild-type and resistant
HIV-1 strains. This suggests that alternative dosing regimens redu-
cing pill burden, improving convenience and adherence or poten-
tially improving adverse events could be prospectively evaluated.
The use of once-daily dosing for treatment-experienced patients,
however, requires close monitoring of treatment adherence and
darunavir concentration measurements, which should be inter-
preted in the light of resistance data.
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